N/A N=142 Preemptive Resuscitation for Eradication of Septic Shock
Sepsis · Severe Sepsis
Primary: Number of Participants With Worsening Organ System Dysfunction Defined by SOFA Score Increase ≥ 1 — 34; 20 Participants — p=0.064
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=246 Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities
Moderate to Severe Plaque Psoriasis
Primary: Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Months 1, 3, 6, and 9 — 31.3; 52.8; 55.8; 57.5 percentage of participants
Phase 2 N=350 Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults
Influenza
Primary: Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain — 5.1; 5.6; 5.3; 5.2 Titers
N/A N=4,856 Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics
Diabetes Mellitus · Cardiovascular Diseases
Primary: Patients Indicated for ACE/ARB and Statin Who Had an Active Prescription for Both — 1279; 1318 Participants
Phase 4 N=245 Does Dual Therapy Hasten Antidepressant Response?
Major Depressive Disorder
Primary: Time to Remission, Defined by the Week of Onset of Persistent Hamilton Rating Scale for Depression (HAM-D 17) <= 7, With no Subsequent HAM-D 17 > 7 — 8; 9; 10 weeks…
N/A N=154 Effect of Local Anesthetic Dose on Interscalene Block
Shoulder Arthroscopy · Interscalene Block
Primary: Handgrip Strength — 6.45; 2.98 kg
N/A N=60 Web-based Intervention to Prevent Risky Driving
Adolescent · Accidents, Traffic · Attention
Primary: Retention of Participants — 28; 28 Participants
Phase 4 N=296 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease
Gastroesophageal Reflux Disease
Primary: Percentage of 24-Hour Heartburn and Acid Regurgitation-Free Days in Non-Erosive Reflux Disease (NERD) Participants — 26.92 percentage of days
Phase 1 N=48 The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy
Heart Failure · Cardiomyopathies
Primary: Change From Baseline in Markers of Cardiac Collagen Turnover (PINP) in Patients With Systolic Heart Failure and Compared With Healthy Controls. — 48.1; 48.1; 39 ng/ml…
Phase 3 N=468 A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in A1C at Week 26 - Excluding Rescue Approach — -0.29; -0.41; -0.26 Percentage — p=0.807
N/A N=40 IMPACT: Inactivity Monitoring and Physical Activity Controlled Trial
Obesity · Cardiovascular Disease · Cancer
Primary: Change in Physical Activity From Baseline to 12 Weeks — -2.25; 50.93 minutes
N/A N=16 OxyGenesys Dissolved Oxygen Dressing; Abdominoplasty at Northwestern University
Wounds
Primary: Healing in Days. — 13.1; 12.5 days
Phase 4 N=301 Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season
Influenza · Healthy
Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 1.7; 0.4 Percentage of participants
N/A N=521 Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Arrhythmia
Primary: Untoward Event Rate Associated With LINQ™ Insertions Performed — 2; 2 Participants — p=<0.001
Phase 2 N=375 Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)
Diabetes Mellitus, Type 2
Primary: Baseline Hemoglobin A1c (HbA1c) — 8.08; 8.01; 7.88; 8.13 Percent